Puma Biotechnology, Inc. reported its financial results for the first quarter ended March 31, 2025. The company announced a net product revenue of $43.1 million from sales of NERLYNX®, representing an increase from $40.3 million in the first quarter of 2024. The company recorded a net income of $3.0 million, or $0.06 per basic and diluted share, compared to a net loss of $4.8 million, or $0.10 per basic and diluted share, in the same period of the previous year. Non-GAAP adjusted net income was $5.0 million, or $0.10 per basic and diluted share, compared to a non-GAAP adjusted net loss of $2.4 million, or $0.05 per basic and diluted share, for the first quarter of 2024. Net cash provided by operating activities totaled $3.6 million, a decrease from $11.3 million in the first quarter of 2024. Puma's cash, cash equivalents, and marketable securities stood at $93.2 million as of March 31, 2025, down from $101.0 million at the end of December 2024. The company highlighted recent clinical developments, including new data on neratinib presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 and anticipated updates from ongoing alisertib clinical studies later in the year. Puma Biotechnology projects its net product revenue for the second quarter of 2025 to be between $48 million and $50 million, with a full-year 2025 estimate unchanged at $192 million to $198 million.